Around $3.5M cash while Market Cap is only $4.8M. Market is crazy and it is massive undervalue.
Patrys Limited (PAB) is a biopharmaceutical company focused on the development
of natural human antibody-based therapies for the treatment of cancer and other
diseases. The Company's headquarter is in Melbourne, Australia, and the main R&D
center is in Wurzburg, Germany.
PAT-SC1: PAT-SC1 is a natural human antibody used to treat gastric cancer and
solid tumours inpatients. PAT-SC1 binds to CD55 target on multiple types of
cancer cells. PAT-SC1 is currently in Phase II for the treatment of gastric
cancer and is in preclinical stage for the treatment of solid tumor. A
commercial partner is being sought for this antibody and discussions are
ongoing.
PAT-SM6: PAT-SM6 is a natural human antibody that has shown promise as a
potential treatment for multiple types of cancer including melanoma. PAT-SM6
targets a protein on the surface of cancer cells called GRP78.Company is
planning for Phase Ib/IIa clinical trial evaluating the effectiveness of PATSM6
in combination with carfilzomib, in patients with relapsed and refractory MM.
PAT-LM1: PAT-LM1 is a natural human antibody that has shown promise in
laboratory and animal testing as a potential treatment for multiple types of
cancer, with a particularly potency against colon, lung, breast, ovary and
pancreatic cancers. PAT-LM1 attacks a protein called non-POU domain-containing
octamer-binding protein (NONO) which is expressed on surface of cancer cells.
PAB has completed preclinical development stage and established commercial scale
manufacturing for PAT-LM1 in the proprietary PER.C6 cell line. The product has
now entered into a scale-up manufacturing process in preparation for future
clinical trial.
OTHER PRODUCTS: PAB has other products in the pipeline that are in discovery
stage, including PAT-SM3, PAT-SM4, PAT-H12
